Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Average Target Price of $12.77 According to Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average rating of “Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.77.

Several research firms have weighed in on TSHA. Wolfe Research started coverage on Taysha Gene Therapies in a research note on Thursday, September 17th. They issued an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, September 21st. Finally, The Goldman Sachs Group upped their price target on Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in Taysha Gene Therapies by 534.7% during the second quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company’s stock worth $27,074,000 after acquiring an additional 3,349,244 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in Taysha Gene Therapies by 19.6% in the third quarter. Pictet Asset Management Holding SA now owns 3,313,062 shares of the company’s stock valued at $16,135,000 after acquiring an additional 542,361 shares during the period. ADAR1 Capital Management LLC increased its holdings in shares of Taysha Gene Therapies by 19.4% in the first quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock worth $13,318,000 after acquiring an additional 483,620 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Taysha Gene Therapies by 53.0% in the first quarter. Rice Hall James & Associates LLC now owns 1,944,671 shares of the company’s stock worth $8,693,000 after acquiring an additional 674,026 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Taysha Gene Therapies by 45.5% during the first quarter. Bank of America Corp DE now owns 1,677,046 shares of the company’s stock worth $7,496,000 after purchasing an additional 524,366 shares during the period. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

TSHA opened at $4.09 on Friday. The company has a fifty day moving average price of $4.67 and a two-hundred day moving average price of $5.30. The firm has a market capitalization of $1.33 billion, a PE ratio of -9.74 and a beta of 1.36. Taysha Gene Therapies has a 52 week low of $3.45 and a 52 week high of $7.30. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, analysts anticipate that Taysha Gene Therapies will post -0.52 earnings per share for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies and other genetic medicine approaches to address disorders that currently have limited or no effective treatment options.

Taysha’s development programs have included TSHA-102 for Rett syndrome, TSHA-101 for GM1 gangliosidosis and TSHA-120 for giant axonal neuropathy.